MSD’s non-oncology sales set to double as Keytruda faces patent cliff
MSD’s expanding non-oncology portfolio is expected to play an increasingly important role in cushioning the impact of Keytruda’s patent cliff.
Unlock FREE Access to Premium Content
Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.
With a free Pharmaceutical Technology profile, you can:
- Access exclusive analyst commentary and expert insights
- View premium forecasts and data-driven pharmaceutical industry insights
- Stay up to date with pharma news, manufacturing innovation, and regulatory developments
- Receive alerts when new premium content is published
Unlock free access
Already have an account? Login herePowered by
